Do analysts rate CMMB or OKYO?

OKYO Pharma has a consensus target price of $5.67, suggesting a potential upside of 265.59%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Chemomab Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 OKYO Pharma 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has preferable valuation & earnings, CMMB or OKYO?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A OKYO Pharma N/A N/A -$8.95M N/A N/A

Is CMMB or OKYO more profitable?

OKYO Pharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -92.14% -82.05% OKYO Pharma N/A N/A N/A

Does the media favor CMMB or OKYO?

In the previous week, Chemomab Therapeutics had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Chemomab Therapeutics and 1 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.89 beat Chemomab Therapeutics' score of -0.67 indicating that OKYO Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative OKYO Pharma 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate GANX or CMMB?

Gain Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 312.09%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Chemomab Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gain Therapeutics 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.67 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is GANX or CMMB more profitable?

Chemomab Therapeutics' return on equity of -92.14% beat Gain Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -161.59% -118.36% Chemomab Therapeutics N/A -92.14% -82.05%

Does the media refer more to GANX or CMMB?

In the previous week, Gain Therapeutics had 7 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 10 mentions for Gain Therapeutics and 3 mentions for Chemomab Therapeutics. Gain Therapeutics' average media sentiment score of 0.27 beat Chemomab Therapeutics' score of -0.67 indicating that Gain Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Do analysts recommend CMMB or TELO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Telomir Pharmaceuticals 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has preferable earnings and valuation, CMMB or TELO?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.91 N/A

Is CMMB or TELO more profitable?

Chemomab Therapeutics' return on equity of -92.14% beat Telomir Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -92.14% -82.05% Telomir Pharmaceuticals N/A -102.70% -90.75%

Do analysts rate CMMB or ANVS?

Annovis Bio has a consensus target price of $12.00, suggesting a potential upside of 775.91%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than Chemomab Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 Annovis Bio 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25

Which has higher valuation and earnings, CMMB or ANVS?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A Annovis Bio N/A N/A -$28.85M -$1.79 N/A

Is CMMB or ANVS more profitable?

Chemomab Therapeutics' return on equity of -92.14% beat Annovis Bio's return on equity. Company Net Margins Return on Equity Return on Assets Chemomab Therapeutics N/A -92.14% -82.05% Annovis Bio N/A -685.98% -258.77%

Does the media favor CMMB or ANVS?

In the previous week, Annovis Bio had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 4 mentions for Annovis Bio and 3 mentions for Chemomab Therapeutics. Annovis Bio's average media sentiment score of 0.41 beat Chemomab Therapeutics' score of -0.67 indicating that Annovis Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative Annovis Bio 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate XBIT or CMMB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher earnings & valuation, XBIT or CMMB?

XBiotech is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio XBiotech N/A N/A -$45.54M -$1.48 N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A

Is XBIT or CMMB more profitable?

XBiotech's return on equity of -31.62% beat Chemomab Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets XBiotech N/A -31.62% -30.29% Chemomab Therapeutics N/A -92.14% -82.05%

Does the media refer more to XBIT or CMMB?

In the previous week, Chemomab Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Chemomab Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 0.58 beat Chemomab Therapeutics' score of -0.67 indicating that XBiotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment XBiotech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Chemomab Therapeutics (CMMB) Competitors

$2.83 +0.10 (+3.66%)

As of 09/3/2026 04:00 PM Eastern

Compare

CMMB vs. OKYO, GANX, TELO, ANVS, and XBIT

Should you buy Chemomab Therapeutics stock or one of its competitors? Chemomab Therapeutics's main competitors and comparable companies include OKYO Pharma (OKYO), Gain Therapeutics (GANX), Telomir Pharmaceuticals (TELO), Annovis Bio (ANVS), and XBiotech (XBIT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Chemomab Therapeutics compare to OKYO Pharma?

Chemomab Therapeutics (NASDAQ:CMMB) and OKYO Pharma (NASDAQ:OKYO) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, dividends, institutional ownership, analyst recommendations, profitability, earnings and media sentiment.

OKYO Pharma's return on equity of 0.00% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-92.14%	-82.05%
OKYO Pharma	N/A	N/A	N/A

46.1% of Chemomab Therapeutics shares are owned by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are owned by institutional investors. 11.9% of Chemomab Therapeutics shares are owned by company insiders. Comparatively, 40.5% of OKYO Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Chemomab Therapeutics has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.03, indicating that its stock price is 97% less volatile than the broader market.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A
OKYO Pharma	N/A	N/A	-$8.95M	N/A	N/A

In the previous week, Chemomab Therapeutics had 2 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for Chemomab Therapeutics and 1 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 1.89 beat Chemomab Therapeutics' score of -0.67 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemomab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
OKYO Pharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

OKYO Pharma has a consensus target price of $5.67, suggesting a potential upside of 265.59%. Given OKYO Pharma's stronger consensus rating and higher probable upside, analysts clearly believe OKYO Pharma is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
OKYO Pharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

OKYO Pharma beats Chemomab Therapeutics on 8 of the 11 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, risk, analyst recommendations, profitability, valuation and earnings.

Chemomab Therapeutics has lower revenue, but higher earnings than Gain Therapeutics. Gain Therapeutics is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,588.50	-$20.16M	-$0.50	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A

Gain Therapeutics has a beta of 0.2, suggesting that its stock price is 80% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Gain Therapeutics presently has a consensus price target of $7.50, indicating a potential upside of 312.09%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Gain Therapeutics had 7 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 10 mentions for Gain Therapeutics and 3 mentions for Chemomab Therapeutics. Gain Therapeutics' average media sentiment score of 0.27 beat Chemomab Therapeutics' score of -0.67 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Chemomab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Chemomab Therapeutics' return on equity of -92.14% beat Gain Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-161.59%	-118.36%
Chemomab Therapeutics	N/A	-92.14%	-82.05%

Summary

Gain Therapeutics and Chemomab Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Telomir Pharmaceuticals?

Chemomab Therapeutics (NASDAQ:CMMB) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Chemomab Therapeutics has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.25, meaning that its stock price is 125% less volatile than the broader market.

In the previous week, Chemomab Therapeutics had 3 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Chemomab Therapeutics and 0 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 0.00 beat Chemomab Therapeutics' score of -0.67 indicating that Telomir Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Chemomab Therapeutics	Negative
Telomir Pharmaceuticals	Neutral

46.1% of Chemomab Therapeutics shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Chemomab Therapeutics' return on equity of -92.14% beat Telomir Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-92.14%	-82.05%
Telomir Pharmaceuticals	N/A	-102.70%	-90.75%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.91	N/A

Summary

Chemomab Therapeutics and Telomir Pharmaceuticals tied by winning 6 of the 12 factors compared between the two stocks.

How does Chemomab Therapeutics compare to Annovis Bio?

Chemomab Therapeutics (NASDAQ:CMMB) and Annovis Bio (NYSE:ANVS) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

Chemomab Therapeutics has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market.

In the previous week, Annovis Bio had 1 more articles in the media than Chemomab Therapeutics. MarketBeat recorded 4 mentions for Annovis Bio and 3 mentions for Chemomab Therapeutics. Annovis Bio's average media sentiment score of 0.41 beat Chemomab Therapeutics' score of -0.67 indicating that Annovis Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Chemomab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative
Annovis Bio	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Annovis Bio has a consensus target price of $12.00, suggesting a potential upside of 775.91%. Given Annovis Bio's stronger consensus rating and higher possible upside, analysts clearly believe Annovis Bio is more favorable than Chemomab Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Annovis Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A
Annovis Bio	N/A	N/A	-$28.85M	-$1.79	N/A

Chemomab Therapeutics' return on equity of -92.14% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Chemomab Therapeutics	N/A	-92.14%	-82.05%
Annovis Bio	N/A	-685.98%	-258.77%

Summary

Annovis Bio beats Chemomab Therapeutics on 9 of the 13 factors compared between the two stocks.

How does Chemomab Therapeutics compare to XBiotech?

XBiotech (NASDAQ:XBIT) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

55.7% of XBiotech shares are owned by institutional investors. Comparatively, 46.1% of Chemomab Therapeutics shares are owned by institutional investors. 30.8% of XBiotech shares are owned by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

XBiotech is trading at a lower price-to-earnings ratio than Chemomab Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
XBiotech	N/A	N/A	-$45.54M	-$1.48	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A

In the previous week, Chemomab Therapeutics had 1 more articles in the media than XBiotech. MarketBeat recorded 3 mentions for Chemomab Therapeutics and 2 mentions for XBiotech. XBiotech's average media sentiment score of 0.58 beat Chemomab Therapeutics' score of -0.67 indicating that XBiotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
XBiotech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Chemomab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

XBiotech has a beta of 0.85, suggesting that its share price is 15% less volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

XBiotech's return on equity of -31.62% beat Chemomab Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
XBiotech	N/A	-31.62%	-30.29%
Chemomab Therapeutics	N/A	-92.14%	-82.05%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

XBiotech beats Chemomab Therapeutics on 7 of the 11 factors compared between the two stocks.

Get Chemomab Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CMMB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CMMB vs. The Competition

Export

Metric	Chemomab Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$19.78M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-1.33	12.66	273.29	25.38
Price / Sales	N/A	1,309.08	613.45	97.56
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	2.36	16.29	12.89	6.14
Net Income	-$8.99M	-$22.72M	$3.47B	$349.01M
7 Day Performance	4.43%	0.34%	0.60%	-0.27%
1 Month Performance	68.45%	8.52%	5.73%	0.68%
1 Year Performance	-7.21%	52.66%	25.35%	14.84%

Chemomab Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CMMB Chemomab Therapeutics	1.114 of 5 stars	$2.83 +3.7%	N/A	-6.3%	$19.78M	N/A	N/A	20	Gap Up
OKYO OKYO Pharma	3.1393 of 5 stars	$1.57 +4.2%	$5.67 +260.0%	-31.7%	$79.25M	N/A	N/A	7	Positive News
GANX Gain Therapeutics	2.4248 of 5 stars	$1.80 +1.7%	$7.50 +316.7%	-5.2%	$77.90M	$50K	N/A	20	Positive News Analyst Revision
TELO Telomir Pharmaceuticals	0.4105 of 5 stars	$1.12 +1.4%	N/A	-1.7%	$76.69M	N/A	N/A	1
ANVS Annovis Bio	2.8927 of 5 stars	$1.73 +2.1%	$11.33 +557.0%	-40.1%	$73.50M	N/A	N/A	3	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CMMB) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. OKYO, GANX, TELO, ANVS, and XBIT

How does Chemomab Therapeutics compare to OKYO Pharma?

Summary

How does Chemomab Therapeutics compare to Gain Therapeutics?

Summary

How does Chemomab Therapeutics compare to Telomir Pharmaceuticals?

Summary

How does Chemomab Therapeutics compare to Annovis Bio?

Summary

How does Chemomab Therapeutics compare to XBiotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Chemomab Therapeutics (CMMB) Competitors

CMMB vs. OKYO, GANX, TELO, ANVS, and XBIT

How does Chemomab Therapeutics compare to OKYO Pharma?

Is CMMB or OKYO more profitable?

Do institutionals & insiders hold more shares of CMMB or OKYO?

Which has more volatility & risk, CMMB or OKYO?

Which has preferable valuation & earnings, CMMB or OKYO?

Does the media favor CMMB or OKYO?

Do analysts rate CMMB or OKYO?

Summary

How does Chemomab Therapeutics compare to Gain Therapeutics?

Which has preferable valuation and earnings, GANX or CMMB?

Which has more risk and volatility, GANX or CMMB?

Do institutionals and insiders believe in GANX or CMMB?

Do analysts rate GANX or CMMB?

Does the media refer more to GANX or CMMB?

Is GANX or CMMB more profitable?

Summary

How does Chemomab Therapeutics compare to Telomir Pharmaceuticals?

Which has more risk & volatility, CMMB or TELO?

Does the media favor CMMB or TELO?

Do institutionals & insiders have more ownership in CMMB or TELO?

Is CMMB or TELO more profitable?

Do analysts recommend CMMB or TELO?

Which has preferable earnings and valuation, CMMB or TELO?

Summary

How does Chemomab Therapeutics compare to Annovis Bio?

Which has more risk and volatility, CMMB or ANVS?

Does the media favor CMMB or ANVS?

Do insiders & institutionals have more ownership in CMMB or ANVS?

Do analysts rate CMMB or ANVS?

Which has higher valuation and earnings, CMMB or ANVS?

Is CMMB or ANVS more profitable?

Summary

How does Chemomab Therapeutics compare to XBiotech?

Do institutionals & insiders believe in XBIT or CMMB?

Which has higher earnings & valuation, XBIT or CMMB?

Does the media refer more to XBIT or CMMB?

Which has more risk and volatility, XBIT or CMMB?

Is XBIT or CMMB more profitable?

Do analysts rate XBIT or CMMB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CMMB vs. The Competition

Chemomab Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools